TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02434796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Peer Groups
Description: In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Peer Groups and Community Dialogues
Description: Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
Study: NCT03506854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection
Study: NCT03576430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active stress handling
Description: biofeed back stress handling
Study: NCT00520494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivaglobin
Description: Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
Study: NCT02073305

Intervention type: OTHER
Intervention: No Sleep Apnea
Description: No intervention

Intervention type: OTHER
Intervention: Sleep Apnea - untreated
Description: No intervention

Intervention type: DEVICE
Intervention: Sleep Apnea - treated
Description: Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
Study: NCT04641754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: tablets, 60 mg→180mg, quaque die（QD）
Study: NCT02643394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: 1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: 400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
Study: NCT03250013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD medications
Study: NCT03471182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric and Cognitive Testing
Description: Interviews, questionnaires, and computer testing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine Self-adminstration
Description: The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
Study: NCT02952937

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 300mg
Description: A new formulation(3rd.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 300mg
Description: A new formulation(3rd.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 300mg
Description: A new formulation(1st.) of Pregabalin CR tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 300mg
Description: A new formulation(1st.) of Pregabalin CR tablet
Study: NCT01408056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% Gel Forming Solution (GFS)
Description: Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% Ointment
Description: Topical application twice per day for 60 days
Study: NCT03174925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Acuson S3000 ultrasound system
Description: Shear Wave Elastography
Study: NCT01343043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.
Study: NCT00605618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-777607
Description: Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
Study: NCT01099618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
Study: NCT01036282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Skill Training
Description: Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT and Social Cognition
Description: Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
Study: NCT05227859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
Study: NCT03419806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCIG (Duodopa)
Description: Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg.
Study: NCT02699437

Intervention type: OTHER
Intervention: Testing for antiphospholipid antibodies
Description: Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
Study: NCT05227859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
Study: NCT03563430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Recovery Group
Description: Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Massage with Foam Roller Group
Description: This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
Study: NCT02083744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsychoEducational Support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard Heart Failure Care
Study: NCT04124731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus anlotinib
Description: Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total.
Study: NCT04191525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BPL-1 Probiotic capsules
Description: BPL-1 Probiotic 1 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo masked with the same presentation as the experimental product 1 capsule/day
Study: NCT03654612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
Study: NCT03690700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFRE
Description: BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BFRE
Description: BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
Study: NCT04302415

Intervention type: DRUG
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment.

Intervention type: DRUG
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment.

Intervention type: DRUG
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment.
Study: NCT02406690

Intervention type: OTHER
Intervention: Estradiol Valerate, Progesterone in Oil, Leuprolide
Description: Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
Study: NCT05243498

Intervention type: OTHER
Intervention: Assessment of the Allogenomic Mismatch Score (AMS)
Description: Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.

Intervention type: OTHER
Intervention: Assessment of the Allogenomic Mismatch Score (AMS)
Description: Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
Study: NCT01188070

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Educational materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: Educational group sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education plus physical exercise
Description: Psychoeducation intervention plus an individualized exercise program
Study: NCT03779100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study: NCT01818037

Intervention type: PROCEDURE
Intervention: Cataract surgery
Study: NCT00534209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic B7.1/HLA-A1
Description: Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given intradermally
Study: NCT02049554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preconception Care Screener
Study: NCT01120522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.
Study: NCT01782950

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
Description: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
Study: NCT02130895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPP Criteria Decision Support Content
Description: 55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with \>=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation.
Study: NCT01032330

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusion treatment
Description: Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
Study: NCT02313519

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics are prepared in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose powder
Study: NCT04382690

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions

Intervention type: BEHAVIORAL
Intervention: All participants will be asked to respond to the same survey questions
Description: All participants will be asked to respond to the same survey questions
Study: NCT03757052

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Penicillin Skin Testing
Description: Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
Study: NCT00739687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-711
Description: 200 mg tablet BID for 9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200 mg tablet BID for 9 months.